C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Receptor interacting protein kinase 2-mediated mitophagy regulates inflammasome activation during virus infection
Christopher R. Lupfer,Paul G. Thomas,Paras K. Anand,Peter Vogel,Sandra Milasta,Jennifer Martinez,Gonghua Huang,Maggie Green,Mondira Kundu,Hongbo Chi,Ramnik J. Xavier,Ramnik J. Xavier,Douglas R. Green,Mohamed Lamkanfi,Mohamed Lamkanfi,Charles A. Dinarello,Peter C. Doherty,Peter C. Doherty,Thirumala-Devi Kanneganti +18 more
TL;DR: A role for NOD2-RIPK2 signaling is demonstrated in protection against virally triggered immunopathology by negatively regulating activation of the NLRP3 inflammasome and production of IL-18 via ULK1-dependent mitophagy.
Journal ArticleDOI
Production of interleukin-1-receptor antagonist during experimental endotoxaemia
Eric V. Granowitz,Debra D. Poutsiaka,Joseph G. Cannon,Sheldon M. Wolff,Charles A. Dinarello,Alfred A. Santos,Douglas W. Wilmore +6 more
TL;DR: The results suggest that the predominant natural response to endotoxin in man is the production of antagonist rather than agonist, which is a hundred-fold greater than those of IL-1 beta.
Journal ArticleDOI
IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist
Frank L. van de Veerdonk,Angela K. Stoeckman,Gouping Wu,Aaron N. Boeckermann,Tania Azam,Mihai G. Netea,Leo A. B. Joosten,Jos W. M. van der Meer,Ruyi Hao,Vassili Kalabokis,Charles A. Dinarello +10 more
TL;DR: Evidence is provided that IL-38 binds to theIL-36R, as does IL-36Ra, and that IL -38 and IL- 36Ra have similar biological effects on immune cells by engaging the IL-37 receptor.
Journal ArticleDOI
Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].
Antonio Abbate,Benjamin W. Van Tassell,Giuseppe Biondi-Zoccai,Michael C. Kontos,John D. Grizzard,Debra Whittaker Spillman,Claudia Oddi,Charlotte S. Roberts,Ryan Melchior,George Mueller,Nayef Abouzaki,Lenore Rosemary Rengel,Amit Varma,Michael Lucas Gambill,Raquel Appa Falcao,Norbert F. Voelkel,Charles A. Dinarello,George W. Vetrovec +17 more
TL;DR: Interleukin-1 blockade with anakinra blunted the acute inflammatory response associated with ST-segment elevation acute myocardial infarction and led to a numerically lower incidence of heart failure in this cohort of clinically stable patients with near-normal LV dimensions and function.
Journal ArticleDOI
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
Carlo Marchetti,Benjamin J Swartzwelter,Fabia Gamboni,Charles Preston Neff,Katrin Richter,Tania Azam,Sonia Carta,Isak W. Tengesdal,Travis Nemkov,Angelo D'Alessandro,Curtis J. Henry,Gerald S. Jones,Scott A. Goodrich,Joseph P. St. Laurent,Terry M. Jones,Curtis L. Scribner,Robert B. Barrow,Roy D. Altman,Damaris B. Skouras,Marco Gattorno,Veronika Grau,Sabina Janciauskiene,Anna Rubartelli,Leo A. B. Joosten,Charles A. Dinarello,Charles A. Dinarello +25 more
TL;DR: It is demonstrated that OLT1177, an orally active β-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome, with unique properties to reverse the metabolic costs of inflammation and to treat IL-1β– and IL-18–mediated diseases.